Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

181.33USD
19 Jan 2018
Change (% chg)

$1.69 (+0.94%)
Prev Close
$179.64
Open
$180.75
Day's High
$181.95
Day's Low
$179.14
Volume
1,042,646
Avg. Vol
673,157
52-wk High
$256.78
52-wk Low
$160.09

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $60,307.29
Shares Outstanding(Mil.): 332.58
Dividend: 0.70
Yield (%): 1.54

Financials

  Industry Sector
P/E (TTM): -- 33.09 17.86
EPS (TTM): -- -- --
ROI: -- 15.01 33.11
ROE: -- 16.57 17.05

Allergan loses bid to avoid Asacol antitrust trial after appellate order

Allergan PLC on Friday lost a last-minute bid to delay an upcoming trial in a class action lawsuit claiming it suppressed generic competition for its ulcerative colitis drug Asacol.

Jan 19 2018

BRIEF-European Commission Approves Amgen, Allergan's Mvasi

* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER

Jan 18 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

Jan 16 2018

BRIEF-Allergan PLC Reports 6.8 Pct Stake In Teva Pharmaceutical Industries As Of January 10, 2018

* ALLERGAN PLC REPORTS 6.8 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF JANUARY 10, 2018 - SEC FILING‍​

Jan 12 2018

BRIEF-‍Pershing Square announces management fee reduction related to Allergan settlement​

* ‍PERSHING SQUARE HOLDINGS, LTD. ANNOUNCES MANAGEMENT FEE REDUCTION RELATED TO ALLERGAN SETTLEMENT

Jan 09 2018

Allergan forecasts 2018 revenue below estimates

Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

Jan 08 2018

UPDATE 1-Allergan forecasts 2018 revenue below estimates

Jan 8 Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

Jan 08 2018

BRIEF-Allergan Anticipates Q4 Net Deferred Tax Benefit Of $3.5 Bln To $4 Bln‍​

* ALLERGAN - CURRENTLY ANTICIPATES RECORDING IN Q4 2017, NET DEFERRED TAX BENEFIT OF $3.5 BILLION TO $4.0 BILLION RELATED TO U.S. TAX CUT AND JOBS ACT‍​

Jan 08 2018

Allergan forecasts 2018 revenue below estimates

Jan 8 Allergan Plc on Monday forecast 2018 revenue below analysts' estimates, hurt by loss of market exclusivity of its products and said it plans to sell its remaining stake in Teva this year.

Jan 08 2018

BRIEF-Allergan Provides Preliminary 2018 Outlook, Update On Teva Holding

* ALLERGAN PROVIDES 2018 PRELIMINARY FINANCIAL OUTLOOK FOR SELECT INCOME STATEMENT CATEGORIES AND OTHER UPDATES

Jan 08 2018

Earnings vs. Estimates